We are live on ! Find out more
PTCT icon

PTC Therapeutics
PTCT

125 hedge funds and large institutions have $636M invested in PTC Therapeutics in 2017 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 42 increasing their positions, 41 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

5.48% more ownership

Funds ownership: 86.37% → 91.86% (+5.5%)

2% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 41

8% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 26

3% less funds holding

Funds holding: 129 → 125 (-4)

11% less capital invested

Capital invested by funds: $715M → $636M (-$79.6M)

20% less funds holding in top 10

Funds holding in top 10: 5 → 4 (-1)

81% less call options, than puts

Call options by funds: $9.17M | Put options by funds: $48M

Holders
125
Holders Change
-4
Holders Change %
-3.1%
% of All Funds
2.84%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.09%
New
24
Increased
42
Reduced
41
Closed
26
Calls
$9.17M
Puts
$48M
Net Calls
-$38.9M
Net Calls Change
+$6.04M

Top Buyers

1
SCM
Scopia Capital Management
New York
+$49.9M
2
State Street
State Street
Massachusetts
+$16.4M
3
RI
RTW Investments
New York
+$10.7M
4
Parallax Volatility Advisers
Parallax Volatility Advisers
California
+$10.7M
5
JGC
J. Goldman & Co
New York
+$10.6M

Top Sellers

1
CCM
Consonance Capital Management
New York
-$79M
2
DAM
DLD Asset Management
New York
-$12.3M
3
NI
Numeric Investors
Massachusetts
-$9.42M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$8M
5
BIM
Bogle Investment Management
Massachusetts
-$6.72M
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
26
Prelude Capital Management
New York
$4.81M +$1.81M +107,090 +59%
Susquehanna International Group
27
Susquehanna International Group
Pennsylvania
$4.42M +$2.15M +127,081 +92%
Two Sigma Investments
28
Two Sigma Investments
New York
$4.2M +$4.26M +251,698 New
Deutsche Bank
29
Deutsche Bank
Germany
$4.08M +$3.12M +184,304 +306%
Renaissance Technologies
30
Renaissance Technologies
New York
$3.78M +$3.84M +226,600 New
QI
31
QS Investors
New York
$3.68M -$144K -8,520 -4%
American Century Companies
32
American Century Companies
Missouri
$3.19M -$89.4K -5,281 -3%
Charles Schwab
33
Charles Schwab
California
$3.14M +$164K +9,693 +5%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$2.99M +$130K +7,693 +4%
Citadel Advisors
35
Citadel Advisors
Florida
$2.84M +$2.88M +170,031 New
Fisher Asset Management
36
Fisher Asset Management
Washington
$2.76M -$125K -7,387 -4%
BIM
37
Bogle Investment Management
Massachusetts
$2.67M -$6.72M -396,777 -71%
Invesco
38
Invesco
Georgia
$2.62M -$1.65M -97,441 -38%
SDIC
39
South Dakota Investment Council
South Dakota
$2.52M -$110K -6,500 -4%
ARTA
40
A.R.T. Advisors
New York
$2.4M +$1.67M +98,800 +219%
Morgan Stanley
41
Morgan Stanley
New York
$2.22M +$497K +29,357 +28%
TCIM
42
TIAA CREF Investment Management
New York
$2.11M +$425K +25,111 +25%
FCM
43
Frontier Capital Management
Massachusetts
$1.75M -$2.4M -142,044 -57%
Citigroup
44
Citigroup
New York
$1.74M +$1.08M +63,772 +158%
CS
45
Candriam SCA
Luxembourg
$1.45M +$457K +27,000 +45%
GC
46
Guggenheim Capital
Illinois
$1.45M +$1.47M +86,908 New
Wells Fargo
47
Wells Fargo
California
$1.27M +$392K +23,164 +44%
UBS Group
48
UBS Group
Switzerland
$1.27M +$206K +12,150 +19%
TA
49
Teachers Advisors
New York
$1.25M +$191K +11,311 +18%
ZIG
50
Zuckerman Investment Group
Illinois
$1.23M +$1.25M +73,683 New
1
2
3 4 5

PTCT Hedge Fund Activity: Q4 2017 in Review

125 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q4 2017, worth a combined $636M — down 11% from $715M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of PTCT and 24 opened new positions — a net loss of 2 holders — while 41 trimmed existing stakes and 42 added.

The largest buyer was Scopia Capital Management, adding an estimated $49.9M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $79M sold.

  • 125 institutional investors held PTC Therapeutics (PTCT) as of Q4 2017, down from 129 in Q3 2017.
  • Funds reported $636M of PTC Therapeutics stock for Q4 2017, down 11% quarter-over-quarter.
  • 24 funds opened new PTC Therapeutics positions in Q4 2017 and 26 closed out, a net change of -2 holders.
  • The largest PTC Therapeutics buyer in Q4 2017 was Scopia Capital Management, an estimated $49.9M added.
  • The largest PTC Therapeutics seller in Q4 2017 was Consonance Capital Management, an estimated $79M sold.

Based on aggregated 13F filings for Q4 2017.